Dornier MedTech Epos Ultra
This article was originally published in The Gray Sheet
Executive SummaryAustralian study of 160 plantar fasciitis patients treated with the extracorporaeal shockwave therapy (ESWT) device finds "no evidence to support a beneficial effect on pain, function and quality of life" compared with placebo at six and 12 weeks. Published in the Sept. 18 Journal of the American Medical Association and conducted by Rachelle Buchbinder, Cabrini Hospital, Victoria, Australia, et al., the study included patients randomized to receive either 1,000 mJ/mm or a placebo dose of 6.0 mJ/mm through three weekly treatments. Both groups showed "significant" improvements in pain and ability, investigators noted. The indication was approved via PMA in January (1"The Gray Sheet" Feb. 4, 2002, p. 25)...
You may also be interested in...
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 9)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this ninth installment of a 10-part series, the experts talk about the importance of maintaining a record of the inspection.
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.